Orexo has successfully navigated a challenging Q116 with the loss of CVS Caremark exclusive status at restricted plans, emerging with positive operating cash flow due to working capital and a focus on cost control (total spend down 17% vs Q4). In the near term, management priorities are Zubsolv revenue growth, balanced with appropriate sales investment to target profitability. Investment will increase as Zubsolv’s market access and reimbursement position improves, and federal legislatio
09 May 2016
Putting CVS Caremark in the past
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Putting CVS Caremark in the past
Orexo has successfully navigated a challenging Q116 with the loss of CVS Caremark exclusive status at restricted plans, emerging with positive operating cash flow due to working capital and a focus on cost control (total spend down 17% vs Q4). In the near term, management priorities are Zubsolv revenue growth, balanced with appropriate sales investment to target profitability. Investment will increase as Zubsolv’s market access and reimbursement position improves, and federal legislatio